Apoptotic mechanisms in mutant LRRK2-mediated cell death

Human Molecular Genetics

Volumn 16, Issue 11, 2007, Pages 1319-1326

  Iaccarino, Ciro ^a,b   Crosio, Claudia ^a,b   Vitale, Carmine ^c,d   Sanna, Giovanna ^a   Carrì, Maria Teresa ^b,e   Barone, Paolo ^c  

^a UNIVERSITY OF SASSARI   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d Istituto di Diagnostica e Cura 'Hermitage' Capodimonte   (Italy)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 3; CASPASE 3 INHIBITOR; CYTOCHROME C; LEUCINE RICH REPEAT KINASE 2;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; MITOCHONDRIAL TOXICITY; NERVE CELL NECROSIS; NEUROPROTECTION; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PATHOLOGY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN DOMAIN; PROTEIN FUNCTION; WESTERN BLOTTING;

APOPTOSIS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; CELL LINE, TUMOR; HUMANS; MITOCHONDRIA; NEURONS; PARKINSON DISEASE; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES;

EID: 34447294546     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddm080     Document Type: Article

References (39)

1. Dauer, W. and Przedborski, S. (2003) Parkinson's disease: Mechanisms and models. Neuron, 39, 889-909.
2. Mouradian, M.M. (2002) Recent advances in the genetics and pathogenesis of Parkinson disease. Neurology, 58, 179-185.
3. Farrer, M.J. (2006) Genetics of Parkinson disease: Paradigm shifts and future prospects. Nat. Rev. Genet., 7, 306-318.
4. Vila, M. and Przedborski, S. (2004) Genetic clues to the pathogenesis of Parkinson's disease. Nat. Med., 10 (suppl.), S58-S62.
5. Ramirez, A., Heimbach, A., Grundemann, J., Stiller, B., Hampshire, D., Cid, L.P., Goebel, I., Mubaidin, A.F., Wriekat, A.L., Roeper, J. et al. (2006) Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat. Genet., 38, 1184-1191.
6. Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., Hulihan, M., Uitti, R.J., Calne, D.B. et al. (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron, 44, 601-607.
7. Paisan-Ruiz, C., Jain, S., Evans, E.W., Gilks, W.P., Simon, J., van der Brug, M., Lopez de Munain, A., Aparicio, S., Gil, A.M., Khan, N. et al. (2004) Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron, 44, 595-600.
8. Adams, J.R., van Netten, H., Schulzer, M., Mak, E., McKenzie, J., Strongosky, A., Sossi, V., Ruth, T.J., Lee, C.S., Farrer, M. et al. (2005) PET in LRRK2 mutations: Comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain, 128, 2777-2785.
9. Bonifati, V. (2006) Parkinson's disease: The LRRK2-G2019S mutation: opening a novel era in Parkinson's disease genetics. Eur. J. Hum. Genet., 14, 1061-1062.
10. Lesage, S., Durr, A. and Brice, A. (2006) LRRK2: A link between familial and sporadic Parkinson's disease? Pathol. Biol. (Paris), 55, 107-110.
11. Smith, W.W., Pei, Z., Jiang, H., Dawson, V.L., Dawson, T.M. and Ross, C.A. (2006) Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci., 9, 1231-1233.
12. West, A.B., Moore, D.J., Biskup, S., Bugayenko, A., Smith, W.W., Ross, C.A., Dawson, V.L. and Dawson, T.M. (2005) Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl Acad. Sci. USA, 102, 16842-16847.
13. Eberhardt, O. and Schulz, J.B. (2003) Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease. Toxicol. Lett., 139, 135-151.
14. Tatton, W.G., Chalmers-Redman, R., Brown, D. and Tatton, N. (2003) Apoptosis in Parkinson's disease: Signals for neuronal degradation. Ann. Neurol., 53 (Suppl. 3), S61-S70; discussion S70-S72.
15. Jellinger, K.A. and Stadelmann, C. (2000) Mechanisms of cell death in neurodegenerative disorders. J. Neural Transm., 59, 95-114.
16. Hanrott, K., Gudmunsen, L., O'Neill, M.J. and Wonnacott, S. (2006) 6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta. J. Biol. Chem., 281, 5373-5382.
17. Smith, W.W., Pei, Z., Jiang, H., Moore, D.J., Liang, Y., West, A.B., Dawson, V.L., Dawson, T.M. and Ross, C.A. (2005) Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl Acad. Sci. USA, 102, 18676-18681.
18. Greggio, E., Jain, S., Kingsbury, A., Bandopadhyay, R., Lewis, P., Kaganovich, A., van der Brug, M.P., Beilina, A., Blackinton, J., Thomas, K.J. et al. (2006) Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis., 23, 329-341.
19. Hengartner, M.O. (2000) The biochemistry of apoptosis. Nature, 407, 770-776.
20. Cozzolino, M., Ferraro, E., Ferri, A., Rigamonti, D., Quondamatteo, F., Ding, H., Xu, Z.S., Ferrari, F., Angelini, D.F., Rotilio, G. et al. (2004) Apoptosome inactivation rescues proneural and neural cells from neurodegeneration. Cell Death Differ., 11, 1179-1191.
21. Taylor, J.P., Mata, I.F. and Farrer, M.J. (2006) LRRK2: A common pathway for parkinsonism, pathogenesis and prevention? Trends Mol. Med., 12, 76-82.
22. Wszolek, Z.K., Pfeiffer, R.F., Tsuboi, Y., Uitti, R.J., McComb, R.D., Stoessl, A.J., Strongosky, A.J., Zimprich, A., Muller-Myhsok, B., Farrer, M.J. et al. (2004) Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology, 62, 1619-1622.
23. Galter, D., Westerlund, M., Carmine, A., Lindqvist, E., Sydow, O. and Olson, L. (2006) LRRK2 expression linked to dopamine-innervated areas. Ann. Neurol., 59, 714-719.
24. Melrose, H., Lincoln, S., Tyndall, G., Dickson, D. and Farrer, M. (2006) Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience, 139, 791-794.
25. Taymans, J.M., Van den Haute, C. and Baekelandt, V. (2006) Distribution of PINK1 and LRRK2 in rat and mouse brain. J. Neurochem., 98 951-961.
26. Simon-Sanchez, J., Herranz-Perez, V., Olucha-Bordonau, F. and Perez-Tur, J. (2006) LRRK2 is expressed in areas affected by Parkinson's disease in the adult mouse brain. Eur. J. Neurosci., 23, 659-666.
27. Macleod, D., Dowman, J., Hammond, R., Leete, T., Inoue, K. and Abeliovich, A. (2006) The familial parkinsonism gene LRRK2 regulates neurite process morphology. Neuron, 52, 587-593.
28. Cozzolino, M., Ferri, A., Ferraro, E., Rotilio, G., Cecconi, F. and Carri, M.T. (2006) Apaf1 mediates apoptosis and mitochondrial damage induced by mutant human SOD1s typical of familial amyotrophic lateral sclerosis. Neurobiol. Dis., 21, 69-79.
29. Mochizuki, H., Hayakawa, H., Migita, M., Shibata, M., Tanaka, R., Suzuki, A., Shimo-Nakanishi, Y., Urabe, T., Yamada, M., Tamayose, K. et al. (2001) An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. Proc. Natl Acad. Sci. USA, 98, 10918-10923.
30. Wang, H., Yu, S.W., Koh, D.W., Lew, J., Coombs, C., Bowers, W., Federoff, H.J., Poirier, G.G., Dawson, T.M. and Dawson, V.L. (2004) Apoptosis-inducing factor substitutes for caspase executioners in NMDA-triggered excitotoxic neuronal death. J. Neurosci., 24, 10963-10973.
31. Biskup, S., Moore, D.J., Celsi, F., Higashi, S., West, A.B., Andrabi, S.A., Kurkinen, K., Yu, S.W., Savitt, J.M., Waldvogel, H.J. et al. (2006) Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol., 60, 557-569.
32. Gloeckner, C.J., Kinkl, N., Schumacher, A., Braun, R.J., O'Neill, E., Meitinger, T., Kolch, W., Prokisch, H. and Ueffing, M. (2006) The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet., 15, 223-232.
33. Abou-Sleiman, P.M., Muqit, M.M. and Wood, N.W. (2006) Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci., 7, 207-219.
34. Palacino, J.J., Sagi, D., Goldberg, M.S., Krauss, S., Motz, C., Wacker, M., Klose, J. and Shen, J. (2004) Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem., 279 18614-18622.
35. Valente, E.M., Abou-Sleiman, P.M., Caputo, V., Muqit, M.M., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A.R., Healy, D.G. et al. (2004) Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science, 304, 1158-1160.
36. Kim, R.H., Smith, P.D., Aleyasin, H., Hayley, S., Mount, M.P., Pownall, S., Wakeham, A., You-Ten, A.J., Kalia, S.K., Horne, P. et al. (2005) Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc. Natl Acad. Sci. USA, 102, 5215-5220.
37. Yaffe, M.B. and Elia, A.E. (2001) Phosphoserine/threonine-binding domains. Curr. Opin. Cell Biol., 13, 131-138.
38. Roth, M.B., Zahler, A.M. and Stolk, J.A. (1991) A conserved family of nuclear phosphoproteins localized to sites of polymerase II transcription. J. Cell Biol., 115, 587-596.
39. Crosio, C., Fimia, G.M., Loury, R., Kimura, M., Okano, Y., Zhou, H., Sen, S., Allis, C.D. and Sassone-Corsi, P. (2002) Mitotic phosphorylation of histone H3: Spatio-temporal regulation by mammalian Aurora kinases. Mol. Cell. Biol., 22, 874-885.